从《遏制微生物耐药国家行动计划(2022-2025年)》谈医疗机构抗微生物药物管理与微生物耐药防控  

Antimicrobial stewardship and prevention and control of antimicrobial resistance in healthcare institutions:a discussion based on the National Action Plan to Combat Antimicrobial Resistance(2022-2025)

作　　者：肖桂荣[1] 宗志勇[2] XIAO Guirong;ZONG Zhiyong(Department of Clinical Pharmacy,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China;Center of Infectious Diseases,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西医院临床药学部(药剂科),成都610041 [2]四川大学华西医院感染性疾病中心,成都610041

出　　处：《华西医学》2023年第3期321-325,共5页West China Medical Journal

基　　金：国家重点研发计划(2022YFC2303900)。

摘　　要：为积极应对微生物耐药带来的挑战,2022年10月国家卫生健康委等13个部门联合印发了《遏制微生物耐药国家行动计划(2022-2025年)》。为推动该行动计划在医疗机构落地,笔者提出了几条防控措施供参考:加强支撑体系与学科建设,强化耐药菌医院感染的预防与控制,推行病原学诊断先行以促进精准诊疗,开展处方点评以促进合理用药,开展普及性和针对性培训,利用信息化手段构建临床决策支持系统,完善监测评价体系,加强多源数据联动与应用。In October 2022,thirteen government departments including the National Health Commission jointly issued the National Action Plan to Combat Antimicrobial Resistance(2022-2025)to proactively address challenges of antimicrobial resistance.In support of the implementation of the National Action Plan in healthcare institutions,the authors put forward following suggestions for prevention and control measures:strengthen construction of supporting systems and disciplines,enhance prevention and control of hospital-acquired infections caused by drug-resistant bacteria,promote precision diagnosis and treatment through diagnostic stewardship,advance rational drug use by performing prescription review,carry out universal and targeted training,establish clinical decision support systems using information technology,improve monitoring and evaluation systems,and enhance multi-source data fusion and application.

关 键 词：微生物耐药 行动计划 抗微生物药物管理 

分 类 号：R446.5[医药卫生—诊断学]